ストックスクリーナーアプリを入手
84.90
1.88%
1.57
アフターアワーズ：
84.90
前日終値:
$83.33
開ける：
$83.99
24時間の取引高:
1.39M
Relative Volume:
1.16
時価総額：
$6.42B
収益：
-
当期純損益:
$-159.39M
株価収益率:
-23.98
EPS:
-3.5401
ネットキャッシュフロー:
$-105.22M
1週間 パフォーマンス:
+3.51%
1か月 パフォーマンス:
+4.78%
6か月 パフォーマンス:
+1,258%
1年 パフォーマンス:
+636.98%
1日の値動き範囲:
$82.56
$85.72
1週間の範囲:
$81.02
$85.72
52週間の値動き範囲:
$4.77
$92.91
Abivax Adr Stock (ABVX) Company Profile
ABVX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABVX
Abivax Adr
|
84.90 | 6.45B | 0 | -159.39M | -105.22M | -3.5401 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Abivax Adr Stock (ABVX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-23 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-03-20 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-12-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-29 | 開始されました | Laidlaw | Buy |
| 2024-05-20 | 開始されました | BTIG Research | Buy |
| 2024-04-29 | 開始されました | Guggenheim | Buy |
| 2024-04-29 | 開始されました | Piper Sandler | Overweight |
| 2023-11-14 | 開始されました | Leerink Partners | Outperform |
| 2023-11-14 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Abivax Adr (ABVX) 最新ニュース
Abivax Reports Increased Losses but Secures Major Funding in H1 2025 - MSN
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 42.1% in August - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), KalVista Pharmaceuticals (KALV) and Argenx Se (ARGX) - The Globe and Mail
Abivax SA Sponsored ADR (NASDAQ:ABVX) Sees Significant Increase in Short Interest - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $95.14 Consensus PT from Brokerages - MarketBeat
Abivax (NASDAQ:ABVX) Shares Gap Down – What’s Next? - Defense World
Octagon Capital Advisors LP Acquires Shares of 1,230,000 Abivax SA Sponsored ADR $ABVX - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Down 38.0% in August - MarketBeat
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of “Buy” by Brokerages - Defense World
Abivax Presents First Half 2025 Financial Results - GlobeNewswire Inc.
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season - FinancialContent
Abivax SA Sponsored ADR $ABVX Stock Position Increased by ADAR1 Capital Management LLC - MarketBeat
Allostery Investments LP Buys 508,401 Shares of Abivax SA Sponsored ADR $ABVX - MarketBeat
Paloma Partners Management Co Purchases Shares of 38,449 Abivax SA Sponsored ADR $ABVX - MarketBeat
Nantahala Capital Management LLC Has $9.27 Million Stock Holdings in Abivax SA Sponsored ADR $ABVX - MarketBeat
Walleye Capital LLC Has $1.38 Million Stock Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Affinity Asset Advisors LLC Takes $1.25 Million Position in Abivax SA Sponsored ADR $ABVX - MarketBeat
Analysts Bullish on Healthcare Stocks: Labcorp Holdings and Abivax SA Sponsored ADR - AInvest
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Abivax (NASDAQ:ABVX) Sets New 12-Month High – What’s Next? - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Short Interest Up 28.7% in July - Defense World
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Analysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Target Price at $92.33 - Defense World
Abivax (NASDAQ:ABVX) Stock Price Up 5.2% on Analyst Upgrade - Defense World
Leerink Partnrs Brokers Reduce Earnings Estimates for Abivax - Defense World
Lifesci Capital Brokers Lift Earnings Estimates for Abivax - Defense World
Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $78.75 - Defense World
Abivax SA Announces $608.6 Million Public Offering of ADSs - The Globe and Mail
Abivax (NASDAQ:ABVX) Reaches New 52-Week High on Analyst Upgrade - Defense World
Abivax SA Stock Surges on Promising Drug Results - TipRanks
Abivax (NASDAQ:ABVX) Trading 577.5% Higher on Analyst Upgrade - Defense World
Abivax SA’s Obefazimod: Strong Phase 3 Results and Promising Market Potential Justify Buy Rating - TipRanks
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS), Abivax SA Sponsored ADR (ABVX) and Kyowa Kirin Co (OtherKYKOF) - The Globe and Mail
Abivax (NASDAQ:ABVX) Hits New 52-Week High on Analyst Upgrade - Defense World
Abivax Hits The Stratosphere, Up Nearly 600%, On 'Potentially Disruptive' Results - Investor's Business Daily
10 Best First Jobs for Aspiring CEOs - inkl
Prologis Inc (PLD) Stock: Navigating Drops and Gains - investchronicle.com
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod - TipRanks
Abivax Reports Positive Phase 3 Results for Ulcerative Colitis Treatment - TipRanks
Grid Metals (CVE:GRDM) Shares Up 44.4% – Here’s What Happened - Defense World
The ICU Stock Puzzle: Unraveling SeaStar Medical Holding Corp’s Fluctuating Performance - investchronicle.com
Citizens JMP reiterates Market Outperform rating on Abivax stock - Investing.com India
Abivax’s Obefazimod: A Promising Contender in Ulcerative Colitis Treatment with Potential Market Impact - TipRanks
Positive Outlook for Abivax SA: Anticipated Success of Obefazimod in Ulcerative Colitis Treatment - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analyst Coverage Updates - The Globe and Mail
Buy Rating Justified for Abivax SA: Promising Efficacy of Obefazimod in Ulcerative Colitis and Crohn’s Disease - TipRanks
Abivax’s Potential in IBD Market: Buy Rating Backed by Phase 3 Trials and Industry Trends - TipRanks
Abivax SA Shareholders Approve 2024 Financials and Board Appointments - TipRanks
Abivax Adr (ABVX) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):